SK bioscience and Thailand’s GPO enter MoU to boost vaccine response
2023-07-06
疫苗
Preview
来源: Pharmaceutical Technology
(From left) Thailand Permanent Secretary of the Ministry of Public Health Dr Opas Karnkawinpong, GPO managing director Dr Mingkwan Suphannaphong, SK bioscience, CEO Jaeyong Ahn and Embassy of the Republic of Korea in Thailand Charge d’affaires ad interim Joyoung Jeon at the MoU at the Ministry of Public Health of Thailand. Credit: SK bioscience.
South Korea-based SK bioscience and the Thailand state-owned pharmaceutical company the Government Pharmaceutical Organisation (GPO) have entered a memorandum of understanding (MoU) to bolster vaccine infrastructure in Thailand.
The deal will enhance the country’s pandemic response system, aiming to produce Thailand’s vaccines locally. It will then be expanded to the wider southeast Asian region.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsClinical Trials - The Expanding Landscape of Regenerative Medicine GlobalData
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Recombinant viral vector-based medicinal preparations GlobalData
View allCompanies IntelligenceSK IncMOU S.A.The Peter Doherty Institute for Infection and ImmunityView all
The two companies will support vaccine development and manufacturing capabilities in Thailand, working together closely in the mid-to-long-term to support the country as a vaccine hub in southeast Asia.
SK bioscience will transfer its cell culture-based influenza vaccine’s production and manufacturing technology to the GPO’s facility.
Following this technology transfer, SK bioscience will provide the vaccine’s processes to the Thai company, which will seek marketing authorisation from the regulators.
The vaccines produced will be used for the national vaccination drive in Thailand.
GPO managing director Dr Mingkwan Suphannaphong stated: “A MoU-signing ceremony between GPO and SK bioscience today substantially contributes to a collaboration on manufacturing the cell-culture based influenza vaccine locally in Thailand, namely the trivalent and quadrivalent inactivated influenza vaccines.
“The drug substance bulk produced by SK will be initially delivered to GPO prior to making the drug products.”
In June 2023, SK bioscience and the Peter Doherty Institute for Infection and ImmunityInfection and Immunity entered a research partnership to develop a next-generation influenza vaccine.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。